Room S2.It was a cold winter’s day in January 2014, and I had just completed my largely overdue first playthrough of Assassin’s Creed. A prospective blood RNA signature for tuberculosis disease risk: a prospective cohort study. Zak DE*, Penn-Nicholson A*, Scriba TJ*, Thompson E, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Hussey GD, Abrahams D, Kafaar F, Hawkridge T, Verver S, Hughes EJ, Ota M, Sutherland J, Howe R, Dockrell HM, Boom WH, Thiel B, Ottenhoff THM, Mayanja-Kizza H, Crampin AC, Downing K, Hatherill M, Valvo J, Shankar S, Parida SK, Kaufmann SHE, Walzl G, Aderem A, Hanekom WA, for other members of the ACS and GC6-74 cohort study teams.
#Rf toolbox version 2.13 torrent serial
Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of M. Nemes E, Rozot V, Geldenhuys H, Bilek N, Mabwe S, Abrahams D, Makhethe L, Erasmus M, Keyser A, Toefy A, Cloete Y, Ratangee F, Blauenfeldt T, Ruhwald M, Walzl G, Smith B, Loxton AG, Hanekom WA, Andrews JR, Lempicki MD, Ellis R, Ginsberg AM, Hatherill M, Scriba TJ C-040-404 Study Team and ACS Study Team. tuberculosis infection to tuberculosis disease. Sequential inflammatory processes define human progression from M. Scriba TJ*, Penn-Nicholson A*, Shankar S*, Hraha T, Thompson EG, Sterling D, Nemes E, Darboe F, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Johnson JL, Boom WH, Hatherill M, Valvo J, De Groote MA, Ochsner UA, Aderem A, Hanekom WA, Zak DE other members of the ACS cohort study team. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, Jayashankar L, Vergara J, Mabwe S, Bilek N, Geldenhuys H, Luabeya AK, Ellis R, Ginsberg AM, Hanekom WA, Reed SG, Coler RN, Scriba TJ*, Hatherill M*. Tom Scriba’s particular interests focus on understanding the immunopathology of Mycobacterium tuberculosis infection and TB disease developing correlates of risk and immunological correlates of protection against TB. The team of over 100 staff consists of specialists in clinical, epidemiological, human immunology and systems biology, clinical trials, community liaison, recruitment, and follow-up data management and analysis, disease surveillance, information technology, clinical evaluation and care of study participants facility management, laboratory technology, logistics, research pharmacy management, project management, regulatory affairs, administration, study coordination and training. Activities are within an academic context, and thus include the training of postgraduate students and postdoctoral fellows. They are testing multiple new vaccine candidates in clinical trials and are involved with projects to address critical clinical, epidemiological, immunological and human genetic questions in TB pathogenesis and vaccine development. SATVI’s mission is the development of new and effective prevention strategies against tuberculosis (TB), including vaccination and biomarker-targeted treatment approaches.
Deputy Director (Immunology), South African Tuberculosis Vaccine Initiative (SATVI), Member of the Institute of Infectious Disease and Molecular Medicine (IDM), Division of Immunology, Department of Pathology, Faculty of Health Sciences, UCT.
0 kommentar(er)
